ROCKET LAB USA INC (RKLB)

US7731221062 - Common Stock

22.41  +2.23 (+11.05%)

After market: 22.2491 -0.16 (-0.72%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RKLB. RKLB was compared to 65 industry peers in the Aerospace & Defense industry. The financial health of RKLB is average, but there are quite some concerns on its profitability. RKLB shows excellent growth, but is valued quite expensive already.



0

1. Profitability

1.1 Basic Checks

In the past year RKLB has reported negative net income.
In the past year RKLB has reported a negative cash flow from operations.
In the past 5 years RKLB always reported negative net income.
RKLB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RKLB has a Return On Assets of -16.33%. This is in the lower half of the industry: RKLB underperforms 72.31% of its industry peers.
RKLB's Return On Equity of -44.86% is on the low side compared to the rest of the industry. RKLB is outperformed by 67.69% of its industry peers.
Industry RankSector Rank
ROA -16.33%
ROE -44.86%
ROIC N/A
ROA(3y)-15.03%
ROA(5y)-17.99%
ROE(3y)-23.3%
ROE(5y)-28.61%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 26.06%, RKLB is in line with its industry, outperforming 56.92% of the companies in the same industry.
RKLB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

RKLB does not have a ROIC to compare to the WACC, probably because it is not profitable.
RKLB has more shares outstanding than it did 1 year ago.
RKLB has a worse debt/assets ratio than last year.

2.2 Solvency

RKLB has an Altman-Z score of 7.55. This indicates that RKLB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.55, RKLB belongs to the top of the industry, outperforming 89.23% of the companies in the same industry.
RKLB has a Debt/Equity ratio of 0.97. This is a neutral value indicating RKLB is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.97, RKLB is not doing good in the industry: 73.85% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF N/A
Altman-Z 7.55
ROIC/WACCN/A
WACC9.06%

2.3 Liquidity

A Current Ratio of 2.58 indicates that RKLB has no problem at all paying its short term obligations.
RKLB has a better Current ratio (2.58) than 64.62% of its industry peers.
A Quick Ratio of 2.16 indicates that RKLB has no problem at all paying its short term obligations.
RKLB has a better Quick ratio (2.16) than 78.46% of its industry peers.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.16

7

3. Growth

3.1 Past

RKLB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.78%.
Looking at the last year, RKLB shows a very strong growth in Revenue. The Revenue has grown by 53.92%.
The Revenue has been growing by 90.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)53.92%
Revenue growth 3Y90.82%
Revenue growth 5YN/A
Sales Q2Q%54.9%

3.2 Future

The Earnings Per Share is expected to grow by 29.07% on average over the next years. This is a very strong growth
Based on estimates for the next years, RKLB will show a very strong growth in Revenue. The Revenue will grow by 43.69% on average per year.
EPS Next Y-4.68%
EPS Next 2Y17.87%
EPS Next 3Y24.85%
EPS Next 5Y29.07%
Revenue Next Year70.74%
Revenue Next 2Y55.12%
Revenue Next 3Y52.98%
Revenue Next 5Y43.69%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RKLB. In the last year negative earnings were reported.
Also next year RKLB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

RKLB's earnings are expected to grow with 24.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.87%
EPS Next 3Y24.85%

0

5. Dividend

5.1 Amount

RKLB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ROCKET LAB USA INC

NASDAQ:RKLB (11/21/2024, 8:00:01 PM)

After market: 22.2491 -0.16 (-0.72%)

22.41

+2.23 (+11.05%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.20B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.33%
ROE -44.86%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 26.06%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.58
Quick Ratio 2.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-2.78%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-4.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)53.92%
Revenue growth 3Y90.82%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y